Primary prevention in hypercholesterolemia: High HDL cholesterol levels and female gender are underestimated protective factors;Primärprevention vid hyperkolesterolemi: Högt HDL-kolesterol och kvinnligt kön underskattade skyddsfaktorer

Lakartidningen

Volumn 103, Issue 3, 2006, Pages 131-134

  Wahlberg, Gustaf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ADULT; BLOOD; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRIMARY PREVENTION; REVIEW; SEX DIFFERENCE;

ADULT; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRIMARY PREVENTION; SEX FACTORS;

EID: 33644843037     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silvershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
2. Bengtsson C, Björkelund C, Lapidus L, Lissner. Association of serum lipid concentrations and obesity with mortality in women: 20 year follow up of participants in prospective population study in Gothenburg, Sweden. BMJ 1993;307:1385-8.
3. Bengtsson C, Björntorp P, Tibblin E. Serum cholesterol and serum triglyceride levels in a population sample of women and in women with ischemic heart disease. Acta Med Scand 1973;suppl 549.
4. de Faire U. Effekter på vaskulära events inklusive cerebrala events, mortalitet och artärer - gränsvärden. Absolut kontra procentuell kolesterolsänkning - primärpreventiva studier. Information från Läkemedelsverket 1999;(7):38-44.
5. Behandlingsrekommendation. Behandling med serumlipidsänkande läkemedel vid prevention av hjärtkärlsjukdom. Information från Läkemedelsverket 2003;(4):9-28.
6. Prevention av aterosklerotisk hjärtkärlsjukdom med lipidreglerande läkemedel. Behandlingsrekommendation. Information från Läkemedelsverket 2005;(1):9-19.
7. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
8. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994;89:1329-445.
9. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15.
10. Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, Gussekloo J, Westendorp RG. High-density vs low-density cholesterol for coronary heart disease and stroke in old age. Arch Internal Med 2004;163:1549-54.
11. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209-16.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
13. Carlson LA. Pensionera serumkolesterolet! Läkartidningen 1978;75:2111-3.
14. Kannel WB. High density lipoprotein: Epidemiologic profile and risks of coronary artery disease. Am J Cardiol 1983;52:9b-72b.
15. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987-1003.
16. Wilhelmsen L, Wedel H, Conroy RM, Fitzgerald T. Det svenska SCORE-diagrammet för kardiovaskulär risk. Läkartidningen 2004;101:1798-801.
17. Wilhelmsen L, Wedel H. Nya europeiska diagram för bedömning av kardiovaskulär risk. Läkartidningen 2003;100:2764-6.
18. Behandling av hyperlipidemi - rekommendationer. Information från Läkemedelsverket 1995;(6):178-86.
19. Durrington PN, Prais H, Bhatnagar D, France M, Crowley V, Khan J, et al. Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet 1999;353:278-81.
20. Castelli WP. Cholesterol and lipids in the risk of coronary heart disease: The Framingham Heart Study. Can J Cardiol 1988;4 Suppl A:5A-10 A.